☆ 4.7 Meeting Abstract

Nivolumab First-Line Therapy for Elderly, Frail Hodgkin Lymphoma Patients: Niviniho, a Lysa Phase II Study

BLOOD (2021)

Journal

BLOOD

Volume 138, Issue -, Pages -

Publisher

AMER SOC HEMATOLOGY

DOI: 10.1182/blood-2021-147863

Keywords

-

Categories

Hematology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Review Biochemistry & Molecular Biology

Incorporating Monoclonal Antibodies into the First-Line Treatment of Classical Hodgkin Lymphoma

Theodoros P. Vassilakopoulos, Athanasios Liaskas, Patricio Pereyra, Panayiotis Panayiotidis, Maria K. Angelopoulou, Andrea Gallamini

Summary: The long-term survival of HL patients is excellent with current standard of care, including combined-modality schedules and treatment intensity adaptation. However, a significant number of patients still experience primary refractory or relapse. Novel immunotherapeutic agents, such as BV and CPI, have shown outstanding efficacy in relapsed/refractory settings. Adding these agents in frontline treatment may further improve disease control and reduce the need for cytotoxic drugs. The results of ongoing phase 3 trials incorporating anti-PD-1 in this setting will provide more insights.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Add to Collection

Article Oncology

Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphoma

Maria A. Garcia-Marquez, Martin Thelen, Sarah Reinke, Diandra Keller, Kerstin Wennhold, Jonas Lehmann, Johanna Veldman, Sven Borchmann, Andreas Rosenwald, Stephanie Sasse, Arjan Diepstra, Peter Borchmann, Andreas Engert, Wolfram Klapper, Michael Von Bergwelt-Baildon, Paul J. Broeckelmann, Hans A. Schloesser

Summary: In this study on classical Hodgkin lymphoma patients, it was found that the exhausted lymphocyte phenotype significantly decreased during first-line anti-PD1 treatment. Additionally, T-cell responses against tumor-associated antigens were observed in some patients, which could be important for immune monitoring and cellular therapy.

LEUKEMIA (2022)

Add to Collection

Editorial Material Oncology

PD-1 inhibitors in patients with Hodgkin lymphoma

Cedric Rossi, Rene-Olivier Casasnovas

Summary: Novel targeted approaches have significantly improved the prognosis of patients with relapsed/refractory Hodgkin lymphoma, especially with the use of inhibitors like Nivolumab and pembrolizumab.

EUROPEAN JOURNAL OF CANCER (2022)

Add to Collection

Article Hematology

Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA study

Vincent Camus, Cedric Rossi, Pierre Sesques, Justine Lequesne, David Tonnelet, Corinne Haioun, Eric Durot, Alexandre Willaume, Martin Gauthier, Marie-Pierre Moles-Moreau, Chloe Antier, Julien Lazarovici, Helene Monjanel, Sophie Bernard, Magalie Tardy, Caroline Besson, Laure Lebras, Sylvain Choquet, Katell Le Du, Christophe Bonnet, Sarah Bailly, Ghandi Damaj, Kamel Laribi, Herve Maisonneuve, Roch Houot, Adrien Chauchet, Fabrice Jardin, Alexandra Traverse-Glehen, Pierre Decazes, Stephanie Becker, Alina Berriolo-Riedinger, Herve Tilly

Summary: Primary mediastinal B-cell lymphoma (PMBL) is a rare, aggressive lymphoma affecting mainly young female patients. This study investigated the outcomes of PMBL patients after different first-line treatments and confirmed the prognostic significance of baseline total metabolic tumor volume (TMTV) in predicting progression-free survival.

BLOOD ADVANCES (2021)

Add to Collection

Article Oncology

Clinical outcomes of relapsed and refractory Hodgkin lymphoma patients after contemporary first-line treatment: a German Hodgkin Study Group analysis

Paul J. Broeckelmann, Horst Mueller, Sarah Gillessen, Xiaoqin Yang, Larissa Koeppel, Veronika Pilz, Patricia Marinello, Peter Kaskel, Monika Raut, Michael Fuchs, Peter Borchmann, Andreas Engert, Bastian von Tresckow

Summary: Evaluation of rrHL patterns after first-line treatment revealed that high-dose chemotherapy and autologous stem-cell transplantation resulted in 10-year progression-free and overall survival rates of 48.2% and 59.4% respectively. Factors such as age and treatment failure significantly influenced patient survival rates.

LEUKEMIA (2022)

Add to Collection

Article Oncology

Optimizing Second-Line Therapy for Hodgkin Lymphoma: A Work in Progress

Nancy L. Bartlett

Summary: The Oncology Grand Rounds series aims to help readers apply key research findings to clinical practice through case studies, literature reviews, and treatment summaries, allowing for better understanding and application.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Optimizing First-Line Therapy for Advanced- Stage Classic Hodgkin Lymphoma

Ranjana H. Advani

Summary: The goal of first-line therapy in classic Hodgkin lymphoma is to balance risk versus benefit to the individual while increasing efficacy and reducing toxicity. The ABVD regimen is well tolerated but slightly less effective, while BV-AVD falls between ABVD and escalated BEACOPP on the cure/morbidity scale. In patients with interim PET-negative cHL, de-escalating therapy does not impact overall survival.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)

Add to Collection

Review Medicine, General & Internal

Classical Hodgkin lymphoma

Pauline Brice, Eric de Kerviler, Jonathan W. Friedberg

Summary: Classical Hodgkin lymphoma is a relatively common lymphoma that is generally considered highly curable with standard first-line chemotherapy and radiotherapy, although some patients may not be cured or may experience late toxic effects leading to premature death. Recent changes in the gold standard of chemotherapy, now often including immunotherapy in relapse settings, have further impacted treatment outcomes.

LANCET (2021)

Add to Collection

Article Hematology

Tumor microenvironment contribution to checkpoint blockade therapy: lessons learned from Hodgkin lymphoma

Antonino Carbone, Annunziata Gloghini, Carmelo Carlo-Stella

Summary: Classic Hodgkin lymphoma (cHL) and B-cell lymphomas have different tumor microenvironments (TMEs) containing inflammatory/immune cells. PD-1-PD ligand 1 pathway blockade drugs have varying effectiveness among refractory/relapsed patients with cHL and B-cell lymphomas. Further research is needed to identify molecules influencing sensitivity or resistance to therapy in individual patients.

BLOOD (2023)

Add to Collection

Review Oncology

Minimising the Toxicities of First Line Hodgkin Lymphoma Treatment in the Modern Era

Annabel M. Follows, Anna Santarsieri

Summary: Due to advances in chemotherapy and radiotherapy, Hodgkin lymphoma is now curable in the majority of younger patients. However, treatment often leads to significant short- and long-term side effects. This article reviews strategies that have been developed to reduce toxicity while maintaining high cure rates and discusses the future direction of treatment incorporating novel agents.

CANCERS (2022)

Add to Collection

Article Hematology

Chemotherapy after PD-1 inhibitors in relapsed/refractory Hodgkin lymphoma: Outcomes and clonal evolution dynamics

Eleonora Calabretta, Anna Guidetti, Francesca Ricci, Martina Di Trani, Chiara Monfrini, Massimo Magagnoli, Stefania Bramanti, Davide Maspero, Lucia Morello, Michele Merli, Alice Di Rocco, Alex Graudenzi, Enrico Derenzini, Marco Antoniotti, Davide Rossi, Paolo Corradini, Armando Santoro, Carmelo Carlo-Stella

Summary: Checkpoint inhibitors (CPIs) are commonly used in relapsed/refractory classical Hodgkin lymphoma, but long-term responses are uncommon and about one-third of patients remain refractory. This study analyzed the response to chemotherapy after CPI failure and characterized the clonal evolution in a small sample of patients. The results showed that most patients achieved complete remission and a small percentage achieved partial remission after chemotherapy rechallenge. Importantly, salvage chemotherapy followed by stem cell transplantation was an effective strategy for rescued CPI failure patients.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

Add to Collection

Article Oncology

SEGHI Study: Defining the Best Surveillance Strategy in Hodgkin Lymphoma after First-Line Treatment

Mariana Bastos Oreiro, Reyes Martin, Pilar Gomez, Nieves Lopez Munoz, Antonia Rodriguez, Marta Liebana, Belen Navarro, Blanca Sanchez-Gonzalez, Pilar Mari, Jaime Perez de Oteiza, Antonio Gutierrez, Leyre Bento, Eva Domingo Domenech, Maria Jesus Vidal, Raquel Del Campo, Elena Perez Ceballos, Maria Infante, Alicia Roldan, Daniel Garcia Belmonte, Miriam Santero, Anna Sureda, Ramon Garcia Sanz

Summary: The optimal strategy for early surveillance after first complete response in Hodgkin lymphoma remains unclear. A study comparing surveillance strategies in a group of 640 patients from 15 different centers in Spain found that imaging surveillance did not improve patient survival or predict relapse. Clinical/analytical surveillance was suggested as a better approach for this group of patients.

CANCERS (2021)

Add to Collection

Article Oncology

Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial

Luc-Matthieu Fornecker, Julien Lazarovici, Igor Aurer, Rene-Olivier Casasnovas, Anne-Claire Gac, Christophe Bonnet, Krimo Bouabdallah, Pierre Feugier, Lena Specht, Lysiane Molina, Mohamed Touati, Cecile Borel, Aspasia Stamatoullas, Emmanuelle Nicolas-Virelizier, Laurent Pascal, Pieternella Lugtenburg, Nicola Di Renzo, Thierry Vander Borght, Alexandra Traverse-Glehen, Peggy Dartigues, Martin Hutchings, Annibale Versari, Michel Meignan, Massimo Federico, Marc Andre

Summary: This study evaluated the efficacy and safety of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (BV-AVD) in early-stage unfavorable Hodgkin lymphoma. The results showed that BV-AVD had a higher PET-negative rate compared to ABVD after two cycles. High total metabolic tumor volume was associated with shorter progression-free survival.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Article Hematology

Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma

Pier Luigi Zinzani, Radhakrishnan Ramchandren, Armando Santoro, Ewa Paszkiewicz-Kozik, Robin Gasiorowski, Nathalie A. Johnson, Jose S. R. de Oliveira, Valeria Buccheri, Guilherme Fleury Perini, Michael Dickinson, Andrew McDonald, Muhit Ozcan, Naohiro Sekiguchi, Ying Zhu, Monika Raut, Todd L. Saretsky, Akash Nahar, John Kuruvilla

Summary: The study demonstrated significant improvements in health-related quality of life measures with pembrolizumab compared to brentuximab vedotin in patients with relapsed or refractory classical Hodgkin lymphoma.

BLOOD ADVANCES (2022)

Add to Collection

Article Hematology

The outcome of older adults with classic Hodgkin lymphoma in British Columbia

Phoebe T. M. Cheng, Diego Villa, Alina S. Gerrie, Ciara L. Freeman, Graham W. Slack, Randy D. Gascoyne, Pedro Farinha, Jeffrey W. Craig, Brian Skinnider, Don Wilson, David W. Scott, Joseph M. Connors, Laurie H. Sehn, Kerry J. Savage

Summary: Outcomes in older adults with classic Hodgkin lymphoma have traditionally been poor, but there has been improvement in recent decades. However, the prognosis for patients aged 70 and above remains unfavorable, even in the modern treatment era. Treatment-related toxicity, particularly associated with bleomycin, is still a significant concern.

BLOOD ADVANCES (2022)

Add to Collection

Article Gastroenterology & Hepatology

Oncogenetic landscape of lymphomagenesis in coeliac disease

Sascha Cording, Ludovic Lhermitte, Georgia Malamut, Sofia Berrabah, Amelie Trinquand, Nicolas Guegan, Patrick Villarese, Sophie Kaltenbach, Bertrand Meresse, Sherine Khater, Michael Dussiot, Marc Bras, Morgane Cheminant, Bruno Tesson, Christine Bole-Feysot, Julie Bruneau, Thierry Jo Molina, David Sibon, Elizabeth Macintyre, Olivier Hermine, Christophe Cellier, Vahid Asnafi, Nadine Cerf-Bensussan

Summary: The study identified mutations activating the JAK1-STAT3 pathway as the main drivers of enteropathy-associated T-cell lymphoma, potentially in combination with mutations in negative regulators of NF-kappa B. These mutations could promote the clonal emergence of malignant lymphocytes in the cytokine-rich coeliac intestine, and are attractive therapeutic targets for treating refractory celiac disease and blocking progression towards EATL.

GUT (2022)

Add to Collection

Correction Hematology

Quality of life of survivors 1 year after the diagnosis of diffuse large B-cell lymphoma: a LYSA study (Oct, 10.1007/s00277-021-04689-4, 2021)

Alexandra-Cristina Paunescu, Christiane Copie Bergman, Sandra Malak, Steven Le Gouill, Vincent Ribrag, Krimo Bouabdallah, David Sibon, Gerhard Rumpold, Marie Preau, Nicolas Mounier, Corinne Haioun, Fabrice Jardin, Caroline Besson

ANNALS OF HEMATOLOGY (2022)

Add to Collection

Article Oncology

Economic burden in non-Hodgkin lymphoma survivors: The French Lymphoma Study Association SIMONAL cross-sectional study

Virginie Nerich, Christophe Guyeux, Michel Henry-Amar, Raphael Couturier, Catherine Thieblemont, Vincent Ribrag, Herve Tilly, Corinne Haioun, Rene-Olivier Casasnovas, Franck Morschhauser, Pierre Feugier, David Sibon, Loic Ysebaert, Emmanuelle Nicolas-Virelizier, Florence Broussais-Guillaumot, Gandhi L. Damaj, Jean-Philippe Jais, Gilles Salles, Macha Woronoff-Lemsi, Nicolas Mounier

Summary: This study focused on the health care resource use and associated costs in 1671 long-term NHL survivors in France. The results showed that most survivors utilized health care resources, with hospitalizations and outpatient treatments being major cost drivers. Several factors were found to have significant relationships with health care costs, but rituximab or autologous stem cell transplantation did not affect costs.

CANCER (2022)

Add to Collection

Letter Hematology

Outcomes of refractory or relapsed Hodgkin lymphoma patients with post-autologous stem cell transplantation brentuximab vedotin maintenance: a French multicenter observational cohort study

Amira Marouf, Anne Segolene Cottereau, Salim Kanoun, Paul Deschamps, Michel Meignan, Patricia Franchi, David Sibon, Clara Antoine, Thomas Gastinne, Cecile Borel, Mohammad Hammoud, Guillaume Sicard, Romane Gille, Doriane Cavalieri, Aspasia Stamatoullas, Lauriane Filliatre-Clement, Julien Lazarovici, Adrien Chauchet, Luc-Matthieu Fornecker, Sandy Amorin, Mathieu Rocquet, Nicole Raus, Barbara Burroni, Marie Therese Rubio, Didier Bouscary, Philippe Quittet, Rene Olivier Casasnovas, Pauline Brice, Herve Ghesquieres, Jerome Tamburini, Benedicte Deau

HAEMATOLOGICA (2022)

Add to Collection

Article Oncology

Positron Emission Tomography-Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study

Rene-Olivier Casasnovas, Reda Bouabdallah, Pauline Brice, Julien Lazarovici, Herve Ghesquieres, Aspasia Stamatoullas, Jehan Dupuis, Anne-Claire Gac, Thomas Gastinne, Bertrand Joly, Krimo Bouabdallah, Emmanuelle Nicolas-Virelizier, Pierre Feugier, Franck Morschhauser, David Sibon, Christophe Bonnet, Alina Berriolo-Riedinger, Veronique Edeline, Marie Parrens, Diane Damotte, Diane Coso, Marc Andre, Michel Meignan, Cedric Rossi

Summary: The AHL2011 study showed that a PET-driven de-escalation strategy after two cycles of BEACOPP is as effective and safe as standard treatment for advanced Hodgkin lymphoma. Extended follow-up data confirmed the non-inferiority of the PET-driven strategy and the prognostic value of PET4 for identifying high-risk patients.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA)

Emmanuel Bachy, Vincent Camus, Catherine Thieblemont, David Sibon, Rene-Olivier Casasnovas, Loic Ysebaert, Gandhi Damaj, Stephanie Guidez, Gian Matteo Pica, Won Seog Kim, Soon Thye Lim, Marc Andre, Alejandro Martin Garcia-Sancho, Maria Jesus Penarrubia, Philipp B. Staber, Judith Trotman, Andreas Huettmann, Vittorio Stefoni, Alessandro Re, Philippe Gaulard, Marie-Helene Delfau-Larue, Laurence de Leval, Michel Meignan, Ju Li, Franck Morschhauser, Richard Delarue

Summary: This study is a randomized phase III study comparing Ro-CHOP with CHOP in previously untreated adult PTCL patients. The study results showed that the addition of romidepsin to CHOP did not improve PFS, response rates, nor overall survival and increased the frequency of grade >= 3 treatment-emergent adverse events.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Biochemistry & Molecular Biology

De novo generation of the NPM-ALK fusion recapitulates the pleiotropic phenotypes of ALK plus ALCL pathogenesis and reveals the ROR2 receptor as target for tumor cells

Loelia Babin, Alice Darchen, Elie Robert, Zakia Aid, Rosalie Borry, Claire Soudais, Marion Piganeau, Anne De Cian, Carine Giovannangeli, Olivia Bawa, Charlotte Rigaud, Jean-Yves Scoazec, Lucile Couronne, Layla Veleanu, Agata Cieslak, Vahid Asnafi, David Sibon, Laurence Lamant, Fabienne Meggetto, Thomas Mercher, Erika Brunet

Summary: This study generated a model of ALK+ ALCL lymphomagenesis by editing the NPM-ALK fusion gene in mature T lymphocytes, and identified the activation of the WNT signaling pathway and the expression of ROR2 as potential therapeutic targets for ALK+ ALCL.

MOLECULAR CANCER (2022)

Add to Collection

Review Oncology

Peripheral T-Cell Lymphomas: Therapeutic Approaches

David Sibon

Summary: Peripheral T-cell lymphomas (PTCLs) are a group of rare malignant tumors with often poor prognosis. Significant progress has been made in recent years through the development of more targeted therapies. This review provides an up-to-date overview of current therapeutic approaches in nodal PTCLs.

CANCERS (2022)

Add to Collection

Article Hematology

Outcomes of older patients with diffuse large B-cell lymphoma treated with R-CHOP: 10-year follow-up of the LNH03-6B trial

Vincent Camus, Aurelien Belot, Lucie Oberic, David Sibon, Herve Ghesquieres, Catherine Thieblemont, Christophe Fruchart, Olivier Casasnovas, Jean-Marie Michot, Thierry Jo Molina, Andre Bosly, Clementine Joubert, Corinne Haioun, Emmanuelle Nicolas-Virelizier, Pierre Feugier, Olivier Fitoussi, Richard Delarue, Herve Tilly

Summary: The study evaluated the efficacy and survival of different treatment regimens in DLBCL patients, and found that the results of the RCHOP-14 and R-CHOP21 groups were similar in terms of PFS and OS. However, progression or relapse after second-line chemotherapy led to poor prognosis, highlighting the need for novel approaches in first-line and alternative treatments.

BLOOD ADVANCES (2022)

Add to Collection

Article Oncology

Outcomes after allogeneic hematopoietic stem cell transplantation for adults with primary mediastinal B cell lymphoma: a SFGM-TC and LYSA study

Baptiste Le Calvez, Benoit Tessoullin, Loic Renaud, Carmen Botella-Garcia, Micha Srour, Steven Le Gouill, Gaelle Guillerm, Remy Gressin, Stephanie Nguyen Quoc, Sabine Furst, Adrien Chauchet, David Sibon, Philippe Lewalle, Xavier Poire, Natacha Maillard, Alban Villate, Michael Loschi, Jerome Paillassa, Yves Beguin, Remy Dulery, Jean-Jacques Tudesq, Amandine Fayard, Marie C. Bene, Vincent Camus, Patrice Chevallier, Amandine Le Bourgeois

Summary: This study indicates that allo-HSCT is a valid therapeutic option for R/R PMBCL, providing durable remissions.

ACTA ONCOLOGICA (2022)

Add to Collection

Editorial Material Hematology

Do we have to exclude all relapsed diffuse large B-cell lymphoma patients not in complete remission from autologous stem cell transplant?

Christian Gisselbrecht, David Sibon

Summary: The CAR-T cell treatment for relapsed/refractory diffuse large B-cell lymphoma poses challenges, and there is debate on whether eligibility criteria should replace standard autologous transplantation. Cherng and colleagues' report suggests that patients with positive residual mass can achieve a five-year survival rate of 54% with standard treatment by using PET-derived parameters.

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Add to Collection

Article Oncology

High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network

Olivier Hermine, Linmiao Jiang, Jan Walewski, Andre Bosly, Catherine Thieblemont, Michal Szymczyk, Christiane Pott, Gilles Salles, Pierre Feugier, Kai Hubel, Corinne Haioun, Rene Olivier Casasnovas, Christian Schmidt, Kamal Bouabdallah, Vincent Ribrag, Lothar Kanz, Jan Durig, Bernd Metzner, David Sibon, Morgane Cheminant, Barbara Burroni, Wolfram Klapper, Wolfgang Hiddemann, Michael Unterhalt, Eva Hoster, Martin Dreyling

Summary: Clinical Trial Updates provide an opportunity to disseminate additional results from studies for which the primary end point has already been reported. This study confirms the previously observed substantially prolonged time to treatment failure and shows an improvement in overall survival for patients with Mantle Cell Lymphoma. Some patients with MCL may be cured.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Article Hematology

Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA group

Raphaelle Aubrais, Krimo Bouabdallah, Loic Chartier, Charles Herbaux, Anne Banos, Pauline Brice, David Sibon, Jean Marc Schiano, Thomas Cluzeau, Kamel Laribi, Ronan Le Calloch, Mathieu Bellal, Baptiste Delapierre, Nicolas Daguindau, Sandy Amorim, Kossi Agbetiafa, Adrien Chauchet, Caroline Besson, Eric Durot, Christophe Bonnet, Ludovic Fouillet, Fontanet Bijou, Olivier Tournilhac, Philippe Gaulard, Marie-Cecile Parrens, Gandhi Damaj

Summary: This study suggests that BBv combination therapy is highly effective and safe for patients with R/R PTCL. Disease status and transplantation are correlated with treatment response and survival. BBv may be the best immunotherapy salvage combination for eligible patients with this condition.

BLOOD ADVANCES (2023)

Add to Collection

Article Hematology

Efficacy of a short sandwich protocol, methotrexate, gemcitabine, L-asparaginase and dexamethasone chemotherapy combined with radiotherapy, in localised newly diagnosed NK/T-cell lymphoma: A French retrospective study

Sammara Chaubard, Amira Marouf, David Lavergne, Francois Lemonnier, Julien Rossignol, Aline Clavert, Remy Gressin, Guillaume Cartron, Agathe Waultier-Rascalou, Jacques Vargaftig, Gilles Salles, Emmanuel Bachy, Herve Ghesquieres, Olivier Tournilhac, Adrien Chauchet, Steven Le Gouill, Gandhi Damaj, Luc-Matthieu Fornecker, David Sibon, Lucie Oberic, Jean-Marie Michot, Philippe Gaulard, Olivier Hermine, Lucile Couronne, Arnaud Jaccard

Summary: We conducted a retrospective multi-center study to evaluate the efficacy of the MGAD regimen combined with 'sandwich' radiotherapy in patients with localized extranodal NK/T-cell lymphoma. The results showed high rates of complete remission and favorable progression-free and overall survival at 2 and 5 years. However, a significant proportion of patients experienced relapse and there were manageable side effects. Monitoring of asparaginase activity revealed drug inactivation in a considerable number of patients. Short-term MGAD chemoradiotherapy appears to be a viable treatment option for newly diagnosed patients with localized extranodal NK/T-cell lymphoma.

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Add to Collection

Article Hematology

Tandem haematopoietic stem cell transplantation versus single cell transplant and BV maintenance in relapsed/refractory Hodgkin lymphoma: A matched cohort analysis from the LYSA

A. Marouf, N. Molinari, D. Sibon, A. S. Cottereau, S. Kanoun, C. Antoine, P. E. Debureaux, D. Cavalieri, L. M. Fornecker, R. O. Casasnovas, C. Herbaux, S. Amorim, C. Rossi, D. Bouscary, P. Brice, H. Ghesquieres, J. Tamburini, B. Deau

Summary: Autologous hematopoietic stem cell transplant (ASCT) is the standard curative treatment for high-risk relapsed/refractory Hodgkin lymphoma (R/R HL) patients. Maintenance therapy with Brentuximab Vedotin (BV) after ASCT has been shown to improve survival in BV-naive patients. In this study, BV maintenance was compared to tandem transplant strategies and was found to be associated with better survival outcomes in patients with high-risk R/R HL.

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.